The DREAM (Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication) trial.

Trial Profile

The DREAM (Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication) trial.

Completed
Phase of Trial: Phase III

Latest Information Update: 22 Apr 2011

At a glance

  • Drugs Ramipril; Rosiglitazone
  • Indications Atherosclerosis; Cardiovascular disorders; Death; Diabetes mellitus; Glucose intolerance; Heart failure; Kidney disorders; Type 2 diabetes mellitus
  • Focus Pharmacodynamics; Therapeutic Use
  • Acronyms DREAM
  • Most Recent Events

    • 22 Apr 2011 Results of an analysis following drug withdrawal published in the Diabetes Care.
    • 20 Sep 2006 Status change
    • 14 Sep 2006 Primary endpoint 'Death-rate' has not been met for ramipril according the results presented at the Annual Meeting of the European Association for the Study of Diabetes.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top